Alvotech, the Icelandic biopharmaceutical company specialising in biosimilars, is anticipating significant growth following its recent listing on the Nasdaq stock exchange. Founder and CEO Róbert Wessman expressed optimism about the company’s trajectory, highlighting the listing as a pivotal step in Alvotech’s expansion strategy.
“The Nasdaq listing provides us with increased visibility and access to a broader investor base, which is essential for our growth plans,” said Wessman. He emphasised that the company is well-positioned to capitalise on the growing demand for biosimilar medicines worldwide.
Alvotech’s focus on developing and manufacturing biosimilars—biological products that are highly similar to already approved reference products—aims to make advanced therapies more accessible and affordable. With a robust pipeline of biosimilar candidates targeting various therapeutic areas, the company is set to play a significant role in the global healthcare landscape.
The successful Nasdaq listing marks a milestone for Alvotech, reflecting investor confidence in its mission and business model. As the company continues to grow, it remains committed to improving patient access to vital biologic medicines.